Shares of Medivation (MDVN) fall 6% premarket. Likely weighing on shares is Johnson &...

|By:, SA News Editor

Shares of Medivation (MDVN) fall 6% premarket. Likely weighing on shares is Johnson & Johnson's acquisition of Aragon, whose prostate cancer drug ARN-509 was the subject of a lawsuit MDVN filed claiming rights to the compound.